Analyst Expectations For Medtronic's Future - Medtronic (NYSE:MDT)

Across the recent three months, 13 analysts have shared their insights on Medtronic (NYSE:MDT), expressing a variety of opinions spanning from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

	Somewhat Bullish	Indifferent
Total Ratings	4	9
Last 30D	0	0
1M Ago	0	0
2M Ago	2	3
3M Ago	2	6

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $95.85, along with a high estimate of $106.00 and a low estimate of $87.00. This current average reflects an increase of 4.28% from the previous average price target of $91.92.

Investigating Analyst Ratings: An Elaborate Study

An in-depth analysis of recent analyst actions unveils how financial experts perceive Medtronic. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Richard Newitter	Truist Securities	Raises	Hold	$93.00	$90.00
Shagun Singh	RBC Capital	Raises	Outperform	$105.00	$98.00
Shagun Singh	RBC Capital	Raises	Sector Perform	$98.00	$92.00
Vijay Kumar	Evercore ISI Group	Raises	Outperform	$104.00	$100.00
Joanne Wuensch	Citigroup	Raises	Neutral	$92.00	$85.00
Richard Newitter	Truist Securities	Raises	Hold	$90.00	$85.00
Matt Miksic	Barclays	Raises	Overweight	$105.00	$104.00
Steven Lichtman	Oppenheimer	Raises	Perform	$94.00	$92.00
Matt O'Brien	Piper Sandler	Raises	Neutral	$90.00	$85.00
Shagun Singh	RBC Capital	Maintains	Sector Perform	$92.00	$92.00
Larry Biegelsen	Wells Fargo	Raises	Overweight	$106.00	$105.00
David Rescott	Baird	Raises	Neutral	$90.00	$82.00
Rick Wise	Stifel	Raises	Hold	$87.00	$85.00

Key Insights:

Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Medtronic. This information provides a snapshot of how analysts perceive the current state of the company.
Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.
Price Targets: Gaining insights, analysts provide estimates for the future value of Medtronic's stock. This comparison reveals trends in analysts' expectations over time.

For valuable insights into Medtronic's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Medtronic analyst ratings.

Get to Know Medtronic Better

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.

A Deep Dive into Medtronic's Financials

Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.

Revenue Growth: Over the 3 months period, Medtronic showcased positive performance, achieving a revenue growth rate of 2.77% as of 31 July, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Medtronic's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 13.16%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Medtronic's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.12%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Medtronic's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.16%, the company may face hurdles in achieving optimal financial performance.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.58.

The Basics of Analyst Ratings

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

MDTMedtronic PLC

$83.280.08%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.